Epilepsy News Archive
Investigators sought to determine whether rectal acetaminophen reduces rates of second febrile seizure in children during the same febrile illness when given rectally shortly after initial seizure.
The FDA has approved the supplemental New Drug Application for Oxtellar XR to include monotherapy use for the treatment of partial-onset seizures patients aged ≥6 years.
Volume Perfusion CT Helps Differentiate Ictal Stroke Mimics, but Not Postictal, From Acute Ischemic Stroke
Patients were initially misjudged to have presented with an acute stroke instead of an epileptic seizure.
Investigators assessed the effect of unplanned vs planned pregnancies in this patient population on the risk for SFL.
The comorbid presence of central apnea has been identified by multiple researchers as predictive of SUDEP.
Investigators evaluated seizure stimulation parameters, electroclinical data, semiology, and anatomical localization in spontaneous and stimulated seizures.
Investigators analyzed the NBEA gene to determine whether or not it could be a biomarker for early childhood epilepsy.
Myoclonic-Atonic Seizures and Lennox-Gastaut Syndrome Present With Overlapping Features, Difficulty in Diagnosis
Patients with a higher number of Lennox-Gastaut syndrome traits had a greater likelihood of ongoing seizures, and each additionally observed Lennox-Gastaut syndrome trait was associated with half the likelihood of achieving seizure freedom.
Compared with nonmotor seizures, there was a significant difference with basal ganglia and thalamus coactivation in terms of seizures with elementary motor signs and automatisms.
Lorcaserin may reduce seizure frequency in patients with Dravet syndrome and severe childhood-onset epilepsies.
The study utilized the Vaccine Safety Datalink and included children who received the first dose of a measles-containing vaccine between 12 and 23 months old during the study period of January 1, 2003 to September 20, 2015.
Investigators assessed the frequency of bilateral independent periodic discharges in patients experiencing electrographic seizures and their effect on patient mortality and clinical outcomes.
Researchers examined a database of seizure-related deaths to determine whether cause was drowning or sudden unexpected death in epilepsy.
Aquestive Therapeutics announced that the FDA has approved Sympazan oral film as adjunctive treatment of seizures associated with LGS in patients aged ≥2 years old.
Researchers used analytic techniques from circular statistics to quantify the prevalence, frequency, and strength of seizure cycles in patients with epilepsy.
Better social competence and adaptive behavior was achieved by seizure-free patients at post-surgery follow-ups compared with patients with persistent seizures (P <.05).
Results suggest that prednisolone may be associated with a reduced chance of achieving electroclinical response when compared with tetracosactide.
The Food and Drug Administration (FDA) approved the treatment in June 2018, making it the first prescription pharmaceutical formulation of highly-purified, plant-derived cannabidiol, as well as the first treatment indicated for patients with Dravet syndrome.
The researchers sought to identify risk factors for seizures in this population by reviewing hospital records.
HFOs were predictors of good or poor surgical outcome in 69.2% of patients, resulting in a modest validation of the researchers' hypothesis.
It is likely that both maternal age and socioeconomic status contribute to the higher rates of pregnancy in WWE compared with women without epilepsy.
Safety data for Fycompa was consistent with the safety profile in adult populations without the need for weight-based dosing.
Drugs with a Schedule V classification have proven medical use and low abuse potential.
The Company states that the NDA is supported by robust clinical trial data, including patients studies where more than 1600 seizures were treated with Valtoco nasal spray.
The odds of language delay were lower at 18 months and 36 months in children exposed to AEDs in utero whose mothers took folic acid.
This widespread variation in strategies may contribute to undesirable outcomes that are characterized by poor seizure control and added deficits.
Although 2 patients experienced an increase in seizure frequency, the remaining patients did not experience a change in frequency.
Countable seizure types were recorded in parents' and caregivers' clinical diaries during a 4-week baseline period.
The investigators sought to detect whether neuroimaging during an emergency department visit was associated with acute changes in the management of patients.
The risk for late-onset epilepsy was lower in patients with higher physical activity levels and moderate alcohol intake.
Recurrence of seizures was reported in 28.2% of patients who attempted withdrawal.
Clobazam is currently available as oral tablets and suspension under the trade name Onfi (Lundbeck).
Approximately 78% of treated patients experienced at least 1 treatment-related adverse event.
The findings offer some reassurance for clinicians and for pregnant women who are successfully treated with enzyme-inducing ACDs.
Diacomit was evaluated in 2 multicenter, placebo-controlled, double-blind, randomized studies.
The results of this review are applicable primarily to persons with focal onset seizures, with 88% of included participants experiencing this type of seizure at baseline.
Investigators assessed demographic and epilepsy-specific factors independently associated with anxiety, including lesions and seizure focus localization.
An expert subcommittee was formed consisting of members of the AAN and AES to update the 2004 evidence-based guidelines on epilepsy treatment with AEDs.
The NDA for IM/IV Captisol-Enabled Fosphenytoin has been accepted for review and given a Prescription Drug Fee User Act date, by the FDA.
Potentially modifiable risk factors in midlife are associated with the risk of developing late-onset epilepsy.
Claims data spanning 4 years were obtained from a pediatric accountable care organization.
The safety and efficacy of clobazam monotherapy in patients with new-onset focal or generalized seizures was investigated in a new Cochrane systematic review.
The efficacy was reported to be significantly higher in patients who had taken benzodiazepines.
Causes of death in patients with epilepsy were assessed to determine the presence of cardiac pathology.
The FDA has approved an abbreviated New Drug Application for Vigadrone, the generic alternative to Sabril powder for oral solution.
Investigators sought to examine whether seizures are capable of causing changes in serotonin levels in the peripheral circulation.
Next-generation sequencing can improve treatment efficacy and reduce hospitalization in children with drug-resistant epilepsy.
This marks the first approved drug that contains an active ingredient derived from marijuana as well as the first treatment approved for patients with Dravet syndrome.
Short-term administration of carbapenem antibiotics may be beneficial in the treatment of VPA overdose in patients with no history of seizure disorder.
Since MRI and EEG risk factors were retrospectively reviewed, the study was unable to analyze the temporal seizure burden or the volume of MRI injury, both of which may have provided greater insights into outcomes.
The primary efficacy outcome was achieved in a higher percentage of patients in the exposure range of 9 to 15 ng/mL compared with patients in the 3 to 7 ng/mL and >7 to 9 ng/mL ranges.
Investigators sought to determine the frequency of major depressive disorder in patients in epilepsy clinics.
The sNDA included data from Study 311 (N=180), an ongoing, open-label, multicenter trial with an extension phase that evaluated the safety, tolerability, and exposure-efficacy relationship of Fycompa oral suspension as adjunctive therapy in children (4 to 11 years) with inadequately controlled POS or PGTC seizures.
The results of this study should help reassure and encourage women with epilepsy without a prior diagnosis of infertility or an associated disorder who are seeking pregnancy.
The effects of short-term VPA exposure on placental compound carrier expression were examined in this study.
A majority of participants (67%) had reported seeing a neurologist or epilepsy specialist in the past year, with younger adults comprising a higher percentage of these participants.
The expanded approval was supported by extrapolated efficacy data from placebo-controlled studies in adults with partial-onset seizures.
The prevalence of major congenital malformations in offspring who are prenatally exposed to antiepileptic drugs is highest among those exposed to carbamazepine, phenobarbital doses of >80 mg/day, valproate of ≤650 mg/day, and levetiracetam at 250 to 4000 mg/day.
The investigators concluded that these findings should help to identify targets for intervention to reduce the overall time to treatment in this population.
The approval was based on a 12-week, double-blind, placebo-controlled study (N=295) in pediatric patients 4-17 years of age.
The approval is specifically for bilateral anterior thalamic nucleus stimulation and is based on results from the SANTE study (Stimulation of the Anterior Nucleus of the Thalamus in Epilepsy).
Although most adults with epilepsy report taking epilepsy medication, less than half of those report having their seizures controlled.
Researchers evaluated the use of genetic screening to identify individuals who are at risk for carbamazepine-induced cutaneous adverse drug reactions.
Investigators conducted a population-based study to assess risk and cause of unnatural mortality in individuals with epilepsy.
Clinicians should conduct a medical evaluation as soon as suspicious symptoms are reported and discontinue lamotrigine if HLH is suspected.
In the event where electroencephalograms featured either seizures or seizure-like patterns, nonexpert medical students who auditorily reviewed the electroencephalograms rated samples as seizures with a higher degree of specificity vs experts or nonexpert medical students.
Cannabidiol may be effective as add-on treatment for drop seizures associated with Lennox-Gastaut syndrome.
The FDA has approved Afinitor Disperz for the adjunctive treatment of patients aged ≥2 years with TSC-associated partial-onset seizures.
The risk of unnatural death is increased among people with epilepsy.
Because of the small size of the study sample, the findings may be limited to this patient population and may be hard to generalize across all pediatric patients with Dravet syndrome.
The small sample size included in the study precludes the ability to make generalized statements about electroencephalogram pattern characteristics in the entire pediatric patient population with BECTS.
Best diagnostics and evidence-based treatments should be used from the start of the disease.
Exposure to sodium valproate or a combination of antiepileptic drugs in utero is associated with worse attainment on national educational tests.
The proposed pediatric indications are based on a 2018 Draft Guidance that supports extrapolating efficacy data of approved drugs to treat POS in adults to pediatric patients aged ≥4 years.
The registers used in this study did not collect information on whether individuals with epilepsy were actually responsible for the transportation accidents.
Pharmaceutical-grade CBD used as adjunctive therapy in patients with pediatric-onset drug-resistant epilepsy may reduce the frequency of seizures.
The findings are limited to the 50 most-prescribed non-epilepsy drugs assessed in this Medicare population and may not generalize to non-Medicare beneficiaries who receive other non-epilepsy drugs.
Cannabinoids are effective as an adjunctive treatment for reducing seizure frequency in pediatric-onset treatment-resistant epilepsy.
Participants in the progressive muscle relaxation group reported greater reductions in stress vs those randomized to the focused-attention activity.
Five studies demonstrated a significant improvement in serum 25-hydroxyvitamin D from baseline to post-treatment vitamin D supplementation in patients with epilepsy.
The study findings are particularly relevant given the current mismatch between clinical practice and regulatory approval of levetiracetam in infantile seizures.
The investigators hope that the consensus statement helps resolve several clinical questions in cases of pediatric new onset status epilepticus syndromes.
School performance is lower in children with prenatal exposure to valproate.
Participants recorded daily mood and stress ratings plus seizure counts using an electronic diary and medication adjustments were not allowed.
While epilepsy-related head trauma was common, 9 of 10 patients displayed no evidence of CTE.
The FDA has cleared the Embrace smart watch for managing epilepsy.
Add-on cannabidiol is associated with reduced monthy drop seizure frequency in patients with Lennox-Gastaut sydrome associated drop seizures.
Clinicians should evaluate their patients, especially patients with focal epilepsy, for mood disorders.
Women receiving topiramate for epilepsy were exposed to high cumulative doses, increasing the risk for oral clefts in offspring.
Patients with tough-to-treat seizures may require nonpharmacologic treatment such as resective surgery.
Over one-third of patients with newly diagnosed epilepsy do not respond to antiepileptic drug treatment.
Vitamin B6 was found to effectively treat the behavioral adverse effects seen with levetiracetam.
Research has found that gabapentin and pregabalin induced myoclonus is often seen but is rarely documented.
Lamotrigine and levetiracetam are just as effective as other AEDs, and are better tolerated as well.
The FDA has accepted for filing with Priority Review the NDA for cannabidiol as seizure treatment.
The findings emphasize the importance of seizure control before pregnancy in women with epilepsy.
Stimulation of the other brain structures resulted in no significant blood pressure changes among the studied participants.
In patients with severe refractory focal epilepsy, add-on treatment with perampanel may be beneficial.
The findings further the utility of cerebral oximetry as a neurological assessment tool.
ZX008 has received Orphan Drug designation and Fast Track designation by the FDA for the treatment of Dravet syndrome.
Neurology Advisor Articles
- Survival in Parkinson Disease Dependent on Parkinsonian Type, Characteristics
- Case Study Report: Herbal Supplement Kratom Associated With Neonatal Abstinence Syndrome
- Mobile Health Apps for Headache: An Ongoing Search for Clinical Relevancy
- CBD Superior to Placebo, Similar to AEDs for Managing Epilepsy Syndromes
- Young Fresh Frozen Plasma Infusion Safe, Feasible in Alzheimer Disease
- Alemtuzumab Linked to Clinical and MRI Disease Remission in Multiple Sclerosis
- Very Early Mobilization After Stroke Does Not Improve Survival Over Usual Care
- Cognitive Decline Worsens With Memantine, ChEIs in Patients With Alzheimer's
- Cervical Dysfunction Needs Clarification to Identify Link With Headache
- Levodopa Inhalation Powder Approved for Parkinson Disease
- Can Early Initiation of Direct Oral Anticoagulants Prevent Recurrent AFib-Related Stroke?
- Hydrocephalus May Be a Complication of Congenial Zika Syndrome
- Higher CSF NfL Protein Levels Linked to Risk for Mild Cognitive Impairment
- Addressing Cognitive Impairment in Pediatric MS: Expert Q&A
- How the Government Shutdown Affects FDA Activities